Alejo J Nevado-Holgado

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2048480/publications.pdf

Version: 2024-02-01

67 papers

2,061 citations

279798 23 h-index 265206 42 g-index

75 all docs

75 docs citations

75 times ranked 3404 citing authors

#	Article	IF	CITATIONS
1	Conditions for the Generation of Beta Oscillations in the Subthalamic Nucleus–Globus Pallidus Network. Journal of Neuroscience, 2010, 30, 12340-12352.	3.6	232
2	NRF2 deficiency replicates transcriptomic changes in Alzheimer's patients and worsens APP and TAU pathology. Redox Biology, 2017, 13, 444-451.	9.0	161
3	CSF1R inhibitor JNJ-40346527 attenuates microglial proliferation and neurodegeneration in P301S mice. Brain, 2019, 142, 3243-3264.	7.6	156
4	Inflammatory biomarkers in Alzheimer's disease plasma. Alzheimer's and Dementia, 2019, 15, 776-787.	0.8	134
5	Effective connectivity of the subthalamic nucleus–globus pallidus network during Parkinsonian oscillations. Journal of Physiology, 2014, 592, 1429-1455.	2.9	84
6	Mental disorders and intimate partner violence perpetrated by men towards women: A Swedish population-based longitudinal study. PLoS Medicine, 2019, 16, e1002995.	8.4	79
7	Association between Plasma Ceramides and Phosphatidylcholines and Hippocampal Brain Volume in Late Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 60, 809-817.	2.6	72
8	A metaboliteâ€based machine learning approach to diagnose Alzheimerâ€ŧype dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 933-938.	3.7	70
9	Oscillatory Activity in the Medial Prefrontal Cortex and Nucleus Accumbens Correlates with Impulsivity and Reward Outcome. PLoS ONE, 2014, 9, e111300.	2.5	68
10	Med7: A transferable clinical natural language processing model for electronic health records. Artificial Intelligence in Medicine, 2021, 118, 102086.	6.5	64
11	Characterising the dynamics of EEG waveforms as the path through parameter space of a neural mass model: Application to epilepsy seizure evolution. NeuroImage, 2012, 59, 2374-2392.	4.2	63
12	Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort. Alzheimer's and Dementia, 2019, 15, 817-827.	0.8	62
13	A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer's disease. Science Advances, 2019, 5, eaau7220.	10.3	59
14	Named entity recognition in electronic health records using transfer learning bootstrapped Neural Networks. Neural Networks, 2020, 121, 132-139.	5.9	57
15	Cross-sectional and longitudinal analyses of outdoor air pollution exposure and cognitive function in UK Biobank. Scientific Reports, 2018, 8, 12089.	3.3	50
16	Commonly prescribed drugs associate with cognitive function: a cross-sectional study in UK Biobank. BMJ Open, 2016, 6, e012177.	1.9	46
17	Red blood cell indices and anaemia as causative factors for cognitive function deficits and for Alzheimerâ \in^{TM} s disease. Genome Medicine, 2018, 10, 51.	8.2	46
18	Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. Alzheimer's and Dementia, 2019, 15, 1478-1488.	0.8	46

#	Article	IF	Citations
19	Natural language processing for structuring clinical text data on depression using UK-CRIS. Evidence-Based Mental Health, 2020, 23, 21-26.	4.5	44
20	The influence of insulin resistance on cerebrospinal fluid and plasma biomarkers of Alzheimer's pathology. Alzheimer's Research and Therapy, 2017, 9, 31.	6.2	36
21	High Blood Pressure and Risk of Dementia: A Two-Sample Mendelian Randomization Study in the UK Biobank. Biological Psychiatry, 2021, 89, 817-824.	1.3	35
22	Urinary metabolic phenotyping for Alzheimer's disease. Scientific Reports, 2020, 10, 21745.	3.3	30
23	Unreliable Evidence: 2 Sources of Uncertainty During Perceptual Choice. Cerebral Cortex, 2015, 25, 937-947.	2.9	28
24	Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [18F]-Flutemetamol PET Scan Result. Frontiers in Aging Neuroscience, 2018, 10, 409.	3.4	28
25	Genetic and Real-World Clinical Data, Combined with Empirical Validation, Nominate Jak-Stat Signaling as a Target for Alzheimer's Disease Therapeutic Development. Cells, 2019, 8, 425.	4.1	27
26	Automatic mining of symptom severity from psychiatric evaluation notes. International Journal of Methods in Psychiatric Research, 2018, 27, e1602.	2.1	24
27	Identifying Predictors of Suicide in Severe Mental Illness: A Feasibility Study of a Clinical Prediction Rule (Oxford Mental Illness and Suicide Tool or OxMIS). Frontiers in Psychiatry, 2020, 11, 268.	2.6	24
28	Associations Between Brain Volumes and Cognitive Tests with Hypertensive Burden in UK Biobank. Journal of Alzheimer's Disease, 2021, 84, 1373-1389.	2.6	19
29	Methotrexate and relative risk of dementia amongst patients with rheumatoid arthritis: a multi-national multi-database case-control study. Alzheimer's Research and Therapy, 2020, 12, 38.	6.2	18
30	ANMerge: A Comprehensive and Accessible Alzheimer's Disease Patient-Level Dataset. Journal of Alzheimer's Disease, 2021, 79, 423-431.	2.6	18
31	Comorbidity between Alzheimer's disease and major depression: a behavioural and transcriptomic characterization study in mice. Alzheimer's Research and Therapy, 2021, 13, 73.	6.2	18
32	Plasma Proteomic Biomarkers Relating to Alzheimer's Disease: A Meta-Analysis Based on Our Own Studies. Frontiers in Aging Neuroscience, 2021, 13, 712545.	3.4	16
33	Determining the Molecular Pathways Underlying the Protective Effect of Non-Steroidal Anti-Inflammatory Drugs for Alzheimer's Disease: A Bioinformatics Approach. Computational and Structural Biotechnology Journal, 2017, 15, 1-7.	4.1	13
34	Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort. Journal of Alzheimer's Disease, 2020, 74, 213-225.	2.6	13
35	Replication study of plasma proteins relating to Alzheimer's pathology. Alzheimer's and Dementia, 2021, 17, 1452-1464.	0.8	13
36	Utilization of the Signature Method to Identify the Early Onset of Sepsis From Multivariate Physiological Time Series in Critical Care Monitoring. Critical Care Medicine, 2020, 48, e976-e981.	0.9	12

#	Article	IF	Citations
37	Real-world effectiveness, its predictors and onset of action of cholinesterase inhibitors and memantine in dementia: retrospective health record study. British Journal of Psychiatry, 2021, 218, 261-267.	2.8	12
38	Validation of UK Biobank data for mental health outcomes: A pilot study using secondary care electronic health records. International Journal of Medical Informatics, 2022, 160, 104704.	3.3	11
39	A Modest Increase in 11C-PK11195-Positron Emission Tomography TSPO Binding in Depression Is Not Associated With Serum C-Reactive Protein or Body Mass Index. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2021, 6, 716-724.	1.5	10
40	Personalised treatment for cognitive impairment in dementia: development and validation of an artificial intelligence model. BMC Medicine, 2022, 20, 45.	5 . 5	9
41	Intact action segmentation in Parkinson's disease: Hypothesis testing using a novel computational approach. Neuropsychologia, 2015, 78, 29-40.	1.6	7
42	Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology. Journal of Alzheimer's Disease, 2020, 77, 1353-1368.	2.6	7
43	Sex-Specific Metabolic Pathways Were Associated with Alzheimer's Disease (AD) Endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery Cohort. Biomedicines, 2021, 9, 1610.	3.2	7
44	A Path Signature Approach for Speech Emotion Recognition. , 0, , .		6
45	The relationship between isolated hypertension with brain volumes in UK Biobank. Brain and Behavior, 2022, 12, e2525.	2.2	6
46	Bifurcation analysis points towards the source of beta neuronal oscillations in Parkinson's disease. , $2011, \dots$		5
47	Genome―and epigenomeâ€wide studies of plasma protein biomarkers for Alzheimer's disease implicate TBCA and TREM2 in disease risk. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12280.	2.4	4
48	[P3â€"232]: A PARKINSON'S DISEASE PROTEIN BIOMARKER PANEL USING THE SOMAMER ASSAY AND MACHINE LEARNING. Alzheimer's and Dementia, 2017, 13, P1027.	0.8	3
49	Effect of trazodone on cognitive decline in people with dementia: Cohort study using UK routinely collected data. International Journal of Geriatric Psychiatry, 2022, 37, .	2.7	2
50	[P4â€"341]: LEVELS OF BLOOD PRESSURE, BODY MASS INDEX AND TOTAL SERUM CHOLESTEROL AT DIFFERENT TIME POINTS PRIOR TO DEMENTIA DIAGNOSIS: A CASE CONTROL STUDY OF OVER 28 MILLION ELECTRONIC HEALTH RECORDS FROM THE EMIF EHR DATA RESOURCE. Alzheimer's and Dementia, 2017, 13, P1420.	0.8	1
51	Identification of plasma proteome signatures associated with ATN framework using SOMAscan. Alzheimer's and Dementia, 2020, 16, e036954.	0.8	1
52	Effect of trazodone on cognitive function in people with dementia: Cohort study using UK routinely collected data. Alzheimer's and Dementia, 2020, 16, e039090.	0.8	1
53	Comparing multiple clustering approaches to understand proteomic datasets for improved biomarker detection. Alzheimer's and Dementia, 2020, 16, e047654.	0.8	1
54	P4â€122: Prevalence of Vascular Risk Factors in Different Stages of Prodromal Alzheimer's Disease and Its Influence on Cognitive Decline. Alzheimer's and Dementia, 2016, 12, P1059.	0.8	0

#	Article	IF	CITATIONS
55	[P3–243]: A MASS SPECTROMETRYâ€BASED DISCOVERY AND REPLICATION OF A MULTIâ€ANALYTE CLASSIFIED NEOCORTICAL AMYLOID PATHOLOGY. Alzheimer's and Dementia, 2017, 13, P1033.	R FOR	O
56	[F1–02–02]: DISCOVERY AND VALIDATION OF MULTIMODAL BIOMARKER SIGNATURES RELATING TO ALZHEIMER'S DISEASE PATHOLOGY AND PROGRESSION. Alzheimer's and Dementia, 2017, 13, P174.	0.8	0
57	[O1–11–06]: EXPLORING THE RELATIONSHIP BETWEEN ANAEMIA AND ALZHEIMER's DISEASE. Alzheimer's ar Dementia, 2017, 13, P221.	nd 0.8	0
58	[O2–18–06]: NOMINATION OF JAK‧TAT SIGNALLING AS A TARGET FOR AD THERAPY THROUGH CLINICAL A MOLECULAR INFORMATICS. Alzheimer's and Dementia, 2017, 13, P604.	ND 0.8	0
59	P3â€233: PLASMA PRIMARY FATTY AMIDES ASSOCIATE TO CSF AMYLOID LEVELS AND ALZHEIMER'S DISEASE PROGRESSION IN THE EMIFâ€AD BIOMARKER DISCOVERY COHORT. Alzheimer's and Dementia, 2018, 14, P1161.	0.8	0
60	F1â€02â€02: DISCOVERY, REPLICATION AND EXTENSION STUDY OF PLASMA PROTEOMIC BIOMARKERS RELATIN TO BRAIN AMYLOID BURDEN AND ALZHEIMER'S DISEASE PROGRESSION. Alzheimer's and Dementia, 2018, 14, P201.	G 0.8	0
61	Teaching old drugs new tricks: Do cardiovascular medications effect cognitive decline?. Alzheimer's and Dementia, 2020, 16, e040554.	0.8	0
62	Identification and validation of plasma proteome signatures associated with MRI measurements in healthy individuals. Alzheimer's and Dementia, 2021, 17 , .	0.8	0
63	Title is missing!. , 2019, 16, e1002995.		0
64	Title is missing!. , 2019, 16, e1002995.		0
65	Title is missing!. , 2019, 16, e1002995.		0
66	Title is missing!. , 2019, 16, e1002995.		0
67	Title is missing!. , 2019, 16, e1002995.		0